XR5944

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
XR5944
DrugBank Accession Number
DB06364
Background

XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 586.7
Monoisotopic: 586.280472367
Chemical Formula
C34H34N8O2
Synonyms
Not Available
External IDs
  • MLN944
  • XR 5944
  • XR-5944
  • XR5944

Pharmacology

Indication

Investigated for use/treatment in solid tumors.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

XR5944 is a novel DNA targeting agent that in preclinical studies has demonstrated a high level of anti-tumor activity, both in vitro and in vivo, against a number of human tumor models. In human tumor xenograft models, treatment with XR5944 caused both partial and complete regression of large established tumors.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
LJH9XG66Q9
CAS number
343247-32-5
InChI Key
SFOADSRLCHRTKT-UHFFFAOYSA-N
InChI
InChI=1S/C34H34N8O2/c1-21-7-3-11-25-29(21)41-31-23(9-5-13-27(31)39-25)33(43)37-19-17-35-15-16-36-18-20-38-34(44)24-10-6-14-28-32(24)42-30-22(2)8-4-12-26(30)40-28/h3-14,35-36H,15-20H2,1-2H3,(H,37,43)(H,38,44)
IUPAC Name
9-methyl-N-(2-{[2-({2-[(9-methylphenazin-1-yl)formamido]ethyl}amino)ethyl]amino}ethyl)phenazine-1-carboxamide
SMILES
[H]N(CCN([H])CCN([H])C(=O)C1=CC=CC2=NC3=CC=CC(C)=C3N=C12)CCN([H])C(=O)C1=CC=CC2=NC3=CC=CC(C)=C3N=C12

References

General References
  1. Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Sharma S, Charlton PA, Norris D, Cree IA: The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. Mol Cancer Ther. 2004 Dec;3(12):1631-7. [Article]
ChemSpider
388219
ChEMBL
CHEMBL30424
ZINC
ZINC000022453042
PDBe Ligand
XR2

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00207 mg/mLALOGPS
logP2.94ALOGPS
logP4.4Chemaxon
logS-5.4ALOGPS
pKa (Strongest Acidic)14.34Chemaxon
pKa (Strongest Basic)9.09Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area133.82 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity167.83 m3·mol-1Chemaxon
Polarizability65.93 Å3Chemaxon
Number of Rings6Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0000090000-e34e6dc700489bed30ce
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014r-0023090000-938f8b1e5ba937e388b3
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0035090000-ab9f22bc5e1cc08dbf91
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-03ki-0139050000-aa208e71db60f7ef0d31
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0230-0296000000-140c65756c01702741f9
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-007d-1279010000-48ff649109d4f3e8b59c
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-231.6122223
predicted
DarkChem Lite v0.1.0
[M-H]-231.2943
predicted
DeepCCS 1.0 (2019)
[M+H]+230.6628223
predicted
DarkChem Lite v0.1.0
[M+H]+233.68987
predicted
DeepCCS 1.0 (2019)
[M+Na]+229.2633223
predicted
DarkChem Lite v0.1.0
[M+Na]+239.60237
predicted
DeepCCS 1.0 (2019)

Drug created at March 19, 2008 16:27 / Updated at June 12, 2020 16:52